Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.52 |
| ▸ | CDK4 | P11802 | 5/20 | 0.50 |
| ▸ | EGFR | P00533 | 5/20 | 0.50 |
| ▸ | AURKA | O14965 | 3/20 | 0.50 |
| ▸ | CCND3 | P30281 | 2/20 | 0.49 |
| ▸ | CCND1 | P24385 | 2/20 | 0.49 |
| ▸ | CCND2 | P30279 | 1/20 | 0.49 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.48 |
| ▸ | CCNK | O75909 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | WEE1 | P30291 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115315 | 0.93 | TNK2 (0.55) | TNK2ALKCDK4EGFRAURKA | |
| SCHEMBL1115422 | 0.89 | CDK4 (0.49) | TNK2CDK4CCND3CCND1CCND2 | |
| SCHEMBL1115190 | 0.87 | AXL (0.50) | TNK2CDK4CCND3CCND1CDK9 | |
| SCHEMBL1115453 | 0.85 | LRRK2 (0.53) | CDK4EGFRAURKACCND3CCNK | |
| SCHEMBL1115436 | 0.81 | WEE1 (0.47) | CDK4CCND3CCND1CCND2CCNA2 | |
| SCHEMBL1115244 | 0.80 | CDK4 (0.49) | CDK4CCND3CCND1CCND2CCNA2 | |
| SCHEMBL1115476 | 0.80 | CDK2 (0.45) | TNK2CDK4CCND3CCND1CCND2 | |
| SCHEMBL2569620 | 0.79 | ALK (0.45) | TNK2ALKCDK4CCND3CCND1 | |
| SCHEMBL12727743 | 0.78 | CDK4 (0.49) | TNK2CDK4CCND3CCND1CCND2 | |
| SCHEMBL1115334 | 0.77 | ALK (0.50) | TNK2ALKCDK4EGFRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | claimed |
| EP-2278973-B1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2011-11-02 | — | — | EP | claimed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | claimed |
| EP-2278973-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | Amgen Inc. (US) | 2011-02-02 | — | — | EP | claimed |
| WO-2009126584-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-10-15 | — | — | WO | claimed |
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2278973-B1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2278973-B1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2278973-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | Amgen Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009126584-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126584-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | CDK4, CDK3, CDK6 | TNK2 1762/4885ALK 2638/4885CDK4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.